The Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND) for MGB Biopharma’s lead candidate MGB-BP-3, for the treatment of clostridium difficile-associated diarrhoea.
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.